{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:17:15Z","timestamp":1790770635475,"version":"4.1.0"},"reference-count":92,"publisher":"American Association for Cancer Research (AACR)","issue":"4","funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["CA208017"],"award-info":[{"award-number":["CA208017"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["CA177292"],"award-info":[{"award-number":["CA177292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["CA214046"],"award-info":[{"award-number":["CA214046"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["CA198183"],"award-info":[{"award-number":["CA198183"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society (ACS)","doi-asserted-by":"publisher","award":["129863-RSG-16-158-01-CDD"],"award-info":[{"award-number":["129863-RSG-16-158-01-CDD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is overexpressed in CLL and is enriched proximal to genes upregulated or de novo expressed in CLL with known functions in disease pathogenesis and progression. These genes, including key members of the B-cell receptor (BCR) signaling pathway, provide a rationale for this therapeutic approach to identify new targets in alternative types of cancer. Additionally, we describe PLX51107, a structurally distinct BET inhibitor with novel in vitro and in vivo pharmacologic properties that emulates or exceeds the efficacy of BCR signaling agents in preclinical models of CLL. Herein, the discovery of the involvement of BRD4 in the core CLL transcriptional program provides a compelling rationale for clinical investigation of PLX51107 as epigenetic therapy in CLL and application of BRD4 profiling in other cancers.<\/jats:p>\n                  <jats:p>Significance: To date, functional studies of BRD4 in CLL are lacking. Through integrated genomic, functional, and pharmacologic analyses, we uncover the existence of BRD4-regulated core CLL transcriptional programs and present preclinical proof-of-concept studies validating BET inhibition as an epigenetic approach to target BCR signaling in CLL. Cancer Discov; 8(4); 458\u201377. \u00a92018 AACR.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 371<\/jats:p>","DOI":"10.1158\/2159-8290.cd-17-0902","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T20:25:42Z","timestamp":1517430342000},"page":"458-477","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor"],"prefix":"10.1158","volume":"8","author":[{"given":"Hatice Gulcin","family":"Ozer","sequence":"first","affiliation":[{"name":"1Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"El-Gamal","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Powell","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Hing","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[{"name":"1Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio."},{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Harrington","sequence":"additional","affiliation":[{"name":"4College of Veterinary Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaneice","family":"Mitchell","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Grieselhuber","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Williams","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzung-Huei","family":"Lai","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Brinton","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Baskin","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cannon","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Beaver","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia M.","family":"Goettl","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Lucas","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Sampath","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Lehman","sequence":"additional","affiliation":[{"name":"5Center for Biostatistics, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianbo","family":"Yu","sequence":"additional","affiliation":[{"name":"5Center for Biostatistics, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Spevak","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyuan","family":"Shi","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Severson","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafe","family":"Shellooe","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Carias","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garson","family":"Tsang","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Dong","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Ewing","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhirai","family":"Marimuthu","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tantoy","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Walters","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sanftner","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Rezaei","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Nespi","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Matusow","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Habets","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewy A.","family":"Math\u00e9","sequence":"additional","affiliation":[{"name":"1Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Bollag","sequence":"additional","affiliation":[{"name":"3Plexxikon Inc., Berkeley, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lapalombella","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"2022060701161106900_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2022060701161106900_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022060701161106900_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060701161106900_bib4","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest"},{"key":"2022060701161106900_bib5","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"2022060701161106900_bib6","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"2022060701161106900_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060701161106900_bib8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"2022060701161106900_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"key":"2022060701161106900_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"2022060701161106900_bib11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022060701161106900_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Del Gaizo Moore","year":"2007","journal-title":"J Clin Invest"},{"key":"2022060701161106900_bib13","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"key":"2022060701161106900_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jcp.20392","article-title":"Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells","volume":"205","author":"Secchiero","year":"2005","journal-title":"J Cell Physiol"},{"key":"2022060701161106900_bib15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/2326-6066.CIR-15-0291","article-title":"Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells","volume":"4","author":"Browning","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2022060701161106900_bib16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bjh.12645","article-title":"B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL","volume":"164","author":"Ferrer","year":"2014","journal-title":"Br J Haematol"},{"key":"2022060701161106900_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4065\/79.3.318","article-title":"Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"79","author":"Ghobrial","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"2022060701161106900_bib18","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V99.8.2977","article-title":"The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes","volume":"99","author":"Till","year":"2002","journal-title":"Blood"},{"key":"2022060701161106900_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"2022060701161106900_bib20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"2022060701161106900_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/gcc.1099","article-title":"TCL1 is activated by chromosomal rearrangement or by hypomethylation","volume":"30","author":"Yuille","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"2022060701161106900_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2014-02-555722","article-title":"Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia","volume":"124","author":"Claus","year":"2014","journal-title":"Blood"},{"key":"2022060701161106900_bib23","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/leu.2014.344","article-title":"miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib","volume":"29","author":"Guinn","year":"2015","journal-title":"Leukemia"},{"key":"2022060701161106900_bib24","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.1038\/ncomms11938","article-title":"Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks","volume":"7","author":"Rendeiro","year":"2016","journal-title":"Nat Commun"},{"key":"2022060701161106900_bib25","doi-asserted-by":"crossref","first-page":"8758","DOI":"10.1073\/pnas.1433065100","article-title":"The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis","volume":"100","author":"Dey","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161106900_bib26","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1017\/S1462399411001992","article-title":"Bromodomains as therapeutic targets","volume":"13","author":"Muller","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"2022060701161106900_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","article-title":"Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4","volume":"19","author":"Yang","year":"2005","journal-title":"Mol Cell"},{"key":"2022060701161106900_bib28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/MCB.01020-07","article-title":"Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression","volume":"28","author":"Yang","year":"2008","journal-title":"Mol Cell Biol"},{"key":"2022060701161106900_bib29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","article-title":"BET bromodomains mediate transcriptional pause release in heart failure","volume":"154","author":"Anand","year":"2013","journal-title":"Cell"},{"key":"2022060701161106900_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"key":"2022060701161106900_bib31","doi-asserted-by":"crossref","first-page":"43137","DOI":"10.1074\/jbc.M112.413047","article-title":"Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells","volume":"287","author":"Zhang","year":"2012","journal-title":"J Biol Chem"},{"key":"2022060701161106900_bib32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"2022060701161106900_bib33","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"2022060701161106900_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"2022060701161106900_bib35","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"2022060701161106900_bib36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol Cell"},{"key":"2022060701161106900_bib37","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161106900_bib38","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol"},{"key":"2022060701161106900_bib39","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol"},{"key":"2022060701161106900_bib40","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161106900_bib41","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","article-title":"Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma","volume":"24","author":"Chapuy","year":"2013","journal-title":"Cancer Cell"},{"key":"2022060701161106900_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature16546","article-title":"Active medulloblastoma enhancers reveal subgroup-specific cellular origins","volume":"530","author":"Lin","year":"2016","journal-title":"Nature"},{"key":"2022060701161106900_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"2022060701161106900_bib44","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/onc.2013.179","article-title":"Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA","volume":"33","author":"Zou","year":"2014","journal-title":"Oncogene"},{"key":"2022060701161106900_bib45","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2006-04-014712","article-title":"JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model","volume":"108","author":"Mercher","year":"2006","journal-title":"Blood"},{"key":"2022060701161106900_bib46","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.celrep.2014.08.025","article-title":"Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition","volume":"8","author":"Bolden","year":"2014","journal-title":"Cell Rep"},{"key":"2022060701161106900_bib47","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1535-7163.MCT-16-0475","article-title":"HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues","volume":"16","author":"Lin","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2022060701161106900_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"2022060701161106900_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bjh.12344","article-title":"Chronic lymphocytic leukaemia\u2014the role of the microenvironment pathogenesis and therapy","volume":"162","author":"Ramsay","year":"2013","journal-title":"Br J Haematol"},{"key":"2022060701161106900_bib50","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006","article-title":"Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells","volume":"95","author":"Decker","year":"2000","journal-title":"Blood"},{"key":"2022060701161106900_bib51","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"2022060701161106900_bib52","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bjc.1984.225","article-title":"Lymphocytic lymphoma\/B-chronic lymphocytic leukaemia\u2013an immunohistopathological study of peripheral B lymphocyte neoplasia","volume":"50","author":"Swerdlow","year":"1984","journal-title":"Br J Cancer"},{"key":"2022060701161106900_bib53","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/sj.leu.2401602","article-title":"Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1)","volume":"13","author":"Mohle","year":"1999","journal-title":"Leukemia"},{"key":"2022060701161106900_bib54","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2007-05-089409","article-title":"Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia","volume":"110","author":"Burkle","year":"2007","journal-title":"Blood"},{"key":"2022060701161106900_bib55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V97.1.256","article-title":"Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome","volume":"97","author":"Fayad","year":"2001","journal-title":"Blood"},{"key":"2022060701161106900_bib56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/intimm\/12.5.631","article-title":"Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development","volume":"12","author":"Solvason","year":"2000","journal-title":"Int Immunol"},{"key":"2022060701161106900_bib57","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060701161106900_bib58","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2013-01-478222","article-title":"Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia","volume":"122","author":"Ferrajoli","year":"2013","journal-title":"Blood"},{"key":"2022060701161106900_bib59","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1182\/blood.V126.23.2752.2752","article-title":"The E\u03bc-Myc\/TCL1 transgenic mouse as a new aggressive B-cell malignancy model suitable for preclinical therapeutics testing","volume":"126","author":"Rogers","year":"2015","journal-title":"Blood"},{"key":"2022060701161106900_bib60","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/leu.2014.9","article-title":"Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells","volume":"28","author":"Zhong","year":"2014","journal-title":"Leukemia"},{"key":"2022060701161106900_bib61","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161106900_bib62","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia","volume":"108","author":"Johnson","year":"2006","journal-title":"Blood"},{"key":"2022060701161106900_bib63","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/MCB.01341-10","article-title":"The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3","volume":"31","author":"Rahman","year":"2011","journal-title":"Mol Cell Biol"},{"key":"2022060701161106900_bib64","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-15-0924","article-title":"BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members","volume":"15","author":"Hogg","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2022060701161106900_bib65","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N Engl J Med"},{"key":"2022060701161106900_bib66","first-page":"432","article-title":"Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas","volume":"15","author":"Jiang","year":"2014","journal-title":"Genome Biol"},{"key":"2022060701161106900_bib67","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood-2015-11-682906","article-title":"IL-4 enhances expression and function of surface IgM in CLL cells","volume":"127","author":"Aguilar-Hernandez","year":"2016","journal-title":"Blood"},{"key":"2022060701161106900_bib68","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.leukres.2007.05.020","article-title":"Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia","volume":"31","author":"Browning","year":"2007","journal-title":"Leuk Res"},{"key":"2022060701161106900_bib69","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.leu.2404017","article-title":"TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state","volume":"20","author":"Herling","year":"2006","journal-title":"Leukemia"},{"key":"2022060701161106900_bib70","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/blood-2009-03-208256","article-title":"High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia","volume":"114","author":"Herling","year":"2009","journal-title":"Blood"},{"key":"2022060701161106900_bib71","doi-asserted-by":"crossref","first-page":"19643","DOI":"10.1073\/pnas.0810965105","article-title":"Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL","volume":"105","author":"Pekarsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161106900_bib72","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1182\/blood.V85.10.2870.bloodjournal85102870","article-title":"Overexpression of cyclin D2 in chronic B-cell malignancies","volume":"85","author":"Delmer","year":"1995","journal-title":"Blood"},{"key":"2022060701161106900_bib73","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/nrc1672","article-title":"The TCL1 family of oncoproteins: co-activators of transformation","volume":"5","author":"Teitell","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2022060701161106900_bib74","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"key":"2022060701161106900_bib75","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2008.07442.x","article-title":"The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia","volume":"144","author":"Nuckel","year":"2009","journal-title":"Br J Haematol"},{"key":"2022060701161106900_bib76","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/onc.2015.245","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016","journal-title":"Oncogene"},{"key":"2022060701161106900_bib77","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"2022060701161106900_bib78","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"2022060701161106900_bib79","first-page":"61","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood","volume":"126","author":"Liu","year":"2015"},{"key":"2022060701161106900_bib80","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"2022060701161106900_bib81","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161106900_bib82","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell reports"},{"key":"2022060701161106900_bib83","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","article-title":"Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia","volume":"120","author":"Lapalombella","year":"2012","journal-title":"Blood"},{"key":"2022060701161106900_bib84","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060701161106900_bib85","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"key":"2022060701161106900_bib86","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2002-03-0844","article-title":"Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a","volume":"100","author":"Graf","year":"2002","journal-title":"Blood"},{"key":"2022060701161106900_bib87","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.yexcr.2006.11.012","article-title":"Single-cell-derived mesenchymal stem cells overexpressing Csx\/Nkx2.5 and GATA4 undergo the stochastic cardiomyogenic fate and behave like transient amplifying cells","volume":"313","author":"Yamada","year":"2007","journal-title":"Exp Cell Res"},{"key":"2022060701161106900_bib88","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1182\/blood.V124.21.2197.2197","article-title":"Expression of PRMT5 in B-cell chronic lymphocytic leukemia and its significance in disease progression and Richter's transformation","volume":"124","author":"El-Gamal","year":"2014","journal-title":"Blood"},{"key":"2022060701161106900_bib89","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","article-title":"Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells","volume":"112","author":"Lapalombella","year":"2008","journal-title":"Blood"},{"key":"2022060701161106900_bib90","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"2022060701161106900_bib91","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat Methods"},{"key":"2022060701161106900_bib92","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat Protoc"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/4\/458\/2942609\/458.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/4\/458\/2942609\/458.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T21:17:07Z","timestamp":1654550227000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/4\/458\/9645\/BRD4-Profiling-Identifies-Critical-Chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":92,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,1]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0902","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22532987","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532984","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532984.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532987.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6546899","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546899.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,1]]}}}